✦ LIBER ✦

1259 POSTER A Phase II Study of Cisplatin Plus S-1 in Patients With Carcinomas of Unknown Primary Site

✍ Scribed by A. Tsuva; T. Kurata; A. Tamiya; I. Okamoto; N. Sugimoto; K. Matsumoto; I. Goto; N. Yamamoto; M. Fukuoka; K. Nakagawa

Book ID: 119578793
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 43 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(11)70871-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of cisplatin /S-1 in pa

A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site

✍ Tsuya, Asuka; Kurata, Takayasu; Tamiya, Akihiro; Okamoto, Isamu; Ueda, Shinya; S 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 145 KB

A randomized Phase II trial in patients

A randomized Phase II trial in patients with carcinoma of an unknown primary site

✍ Jonathan E. Dowell; Audrey M. Garrett; Yu Shyr; David H. Johnson; Kenneth R. Han 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

Phase II study of cisplatin, 5-fluoroura

Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin

✍ Raber, Martin N.; Frost, Philip; Schmidt, Susan; Abbruzzese, James L.; Lenzi, Re 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Phase II trial of carboplatin, gemcitabi

Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site

✍ Bryan J. Schneider; Basil El-Rayes; Jeffery H. Muler; Philip A. Philip; Gregory 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND. The purposes of this study were to evaluate efficacy and toxicity of the combination of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (CUP). ## METHODS. Patients with CUP received carboplatin AUC 5 mg/mL a minute intraven

Cisplatin and gemcitabine with either vi

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : Results of an Italian Multicenter, randomized, phase II study

✍ Sergio Palmeri; Vito Lorusso; Laura Palmeri; Marina Vaglica; Camillo Porta; Rola 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 1 views

## Abstract ## BACKGROUND. To date, the standard treatment for patients who have carcinoma of unknown primary site has not been established. ## METHODS. In this randomized Phase II study, 66 previously untreated patients (33 patients per arm) with carcinomas of unknown primary site received cisp

Extended safety and efficacy data on S-1

Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study

✍ Heinz-Joseph Lenz; Fa-Chyi Lee; Daniel G. Haller; Deepti Singh; Al B. Benson III 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB

## Abstract ## BACKGROUND. S‐1 is a promising oral fluoropyrimidine. The authors obtained extended Phase II safety and efficacy data in a multicenter setting for the S‐1 plus cisplatin combination: The experimental arm of the global Phase III First‐Line Advanced Gastric Cancer Study (FLAGS) is bei